Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

INSIDE INDUSTRY
BioScience Managers expands Asia Pacific presence
Leading Asia Pacific healthcare fund manager, BioScience Managers Pty Ltd, announced a $3m investment in innovative New Zealand asthma technology company, Nexus6.

Nexus6’s SmartInhaler product remotely monitors adherence to asthma treatment regimes, ensuring patients comply with treatment protocols in general use and in clinical trials, giving clinicians transparency over inhaler use and dosage in real time.

“Nexus6 technology holds the key to not only ensuring better patient outcomes, but also in minimizing wastage and costs of treatment, by ensuring that asthma sufferers take only what they need and when they need it,” said BioScience Managers Managing Director, Jeremy Curnock Cook.

“In the current climate, technologies that enable remote monitoring of patients and support the delivery of better health outcomes, for less cost and with less wastage, are extremely important. Nexus6 also provides a unique supporting technology for asthma clinical trials.”

Nexus6 marks BioScience Managers’ second investment from its Asia Pacific Healthcare Fund II. The AU$55m fund is still open to investors, with a final close expected in September 2013. The investment was also supported by up to $2m raised from existing investors, including leading NZ venture firm K1W1.

The firm is increasingly active in the medical technologies space, providing investment management services to Plus listed UnionMedtech (UMT). UMT marks the first of a planned series of tailored investment vehicles to bring together investor appetite for specific aspects of healthcare with technologies sourced from around the globe.

BioScience Managers Chief Investment Officer Matt McNamara commented, “The healthcare sector is increasingly important at a global macroeconomic level, with both the cost and the effectiveness of healthcare solutions coming under increasing scrutiny.”

“We believe there is a significant opportunity in the investment in and consolidation of medical technologies from around the world to enable those companies better access to international markets and economies of scale across synergistic businesses.”

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.